P640: ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)
Barbara Eichhorst,
Nicole Lamanna,
Susan O’brien,
Constantine Tam,
Lugui Qiu,
Keri Yang,
Ken Wu,
Tommi Salmi,
Gisoo Barnes,
Jennifer R. Brown
Affiliations
Barbara Eichhorst
1 University of Cologne, Center for Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, Department of Internal Medicine, Cologne, Germany
Nicole Lamanna
2 Herbert Irving Comprehensive Cancer Center, Columbia University, New York, United States
Susan O’brien
3 Chao Family Comprehensive Cancer Center, University of California, Irvine, United States
Constantine Tam
4 Alfred Health and Monash University, Melbourne, Australia
Lugui Qiu
5 Poznan University of Medical Sciences, Department of Hematology and Bone Marrow Transplantation, Poznan, Poland
Keri Yang
6 BeiGene USA, Inc., San Mateo, United States
Ken Wu
7 BeiGene (Beijing) Co., Ltd., and BeiGene USA, Inc., Beijing, China
Tommi Salmi
8 BeiGene International, GmbH, Basel, Switzerland
Gisoo Barnes
6 BeiGene USA, Inc., San Mateo, United States
Jennifer R. Brown
9 Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, United States